BioNTech SE vs Merck & Company, Inc. — Stock Comparison
Q·Score Breakdown
4.6
Underperform
Overall
7.3
Buy
Quality
Health
Growth
Valuation
Sentiment
BNTX
Clean balance sheet with low leverage (0.0× debt-to-equity).
⚠ currently unprofitable (-40% margin).
MRK
High-quality business with 37% return on equity and 28% profit margins.
⚠ earnings contracting 19% year-over-year.
Analyst Consensus
BUY
Target $130.86 (+25.5%)
18 analysts
BUY
Target $129.74 (+17.3%)
27 analysts
Fundamentals
BNTX
MRK
—
Trailing P/E
15.2×
-23.3×
Forward P/E
11.4×
-39.6%
Profit Margin
28.1%
78.7%
Gross Margin
77.2%
-5.9%
ROE
36.9%
-23.7%
Revenue Growth
5.0%
—
Earnings Growth
-19.3%
1.59
Beta
0.28
—
Price / Book
—
$26.4B
Market Cap
$273.2B
$80 – $124
52-Week Range
$73 – $125
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load.